Skip to main content

Schoenberg Mark's Form 4 filing

UroGen Pharma Ltd. (URGN) · filed Feb 2, 2022

Accession no.
0001209191-22-006384
Filed
Feb 2, 2022
Trade date
Jan 31, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 4 derivative transactions. Open-market sales total $10.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Schoenberg MarkCIK 0001763581Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 31, 2022Ordinary SharesMOption exerciseAcquired+500––22,595Direct
Jan 31, 2022Ordinary SharesSSaleDisposed−275$7.58−$2,084.522,320Direct
Jan 31, 2022Ordinary SharesMOption exerciseAcquired+2,000––24,320Direct
Jan 31, 2022Ordinary SharesSSaleDisposed−1,099$7.58−$8,330.4223,221Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 31, 2022Ordinary SharesMOption exerciseDisposed−500$0.00$02,000Direct
Jan 31, 2022Ordinary SharesAGrant or awardAcquired+12,064$0.00$012,064Direct
Jan 31, 2022Ordinary SharesAGrant or awardAcquired0$0.00$04,000Direct
Jan 31, 2022Ordinary SharesMOption exerciseDisposed−2,000$0.00$04,000Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)